Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR

Legal & General Group Plc bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 270,875 shares of the company’s stock, valued at approximately $2,760,000. Legal & General Group Plc owned approximately 0.16% of Vir Biotechnology as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of VIR. CWM LLC raised its stake in shares of Vir Biotechnology by 23.0% during the 4th quarter. CWM LLC now owns 8,804 shares of the company’s stock worth $53,000 after purchasing an additional 1,646 shares in the last quarter. ProShare Advisors LLC increased its holdings in Vir Biotechnology by 7.8% during the fourth quarter. ProShare Advisors LLC now owns 23,525 shares of the company’s stock worth $142,000 after buying an additional 1,705 shares during the last quarter. Rhumbline Advisers increased its holdings in Vir Biotechnology by 1.0% during the second quarter. Rhumbline Advisers now owns 228,949 shares of the company’s stock worth $1,154,000 after buying an additional 2,300 shares during the last quarter. Corient Private Wealth LLC raised its position in Vir Biotechnology by 1.0% during the fourth quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock worth $1,572,000 after acquiring an additional 2,515 shares in the last quarter. Finally, Focus Partners Wealth raised its position in Vir Biotechnology by 15.3% during the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after acquiring an additional 2,566 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

VIR has been the subject of a number of research analyst reports. Morgan Stanley set a $25.00 price target on Vir Biotechnology in a report on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating on shares of Vir Biotechnology in a research report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Leerink Partners boosted their target price on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Finally, Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.57.

Vir Biotechnology Stock Down 0.5%

Shares of VIR stock opened at $11.39 on Friday. Vir Biotechnology, Inc. has a twelve month low of $4.75 and a twelve month high of $11.94. The business has a fifty day simple moving average of $9.74 and a 200 day simple moving average of $9.44. The company has a market cap of $1.93 billion, a P/E ratio of -6.12 and a beta of 1.63.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14. The firm had revenue of $238.95 million during the quarter, compared to analysts’ expectations of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. The business’s revenue for the quarter was up 19582.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.80) earnings per share. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.